Insider Selling: Vera Therapeutics (NASDAQ:VERA) Insider Sells $66,412.36 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) insider Laurence Matthew Skelton sold 1,582 shares of the company’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $66,412.36. Following the completion of the transaction, the insider directly owned 64,218 shares of the company’s stock, valued at $2,695,871.64. The trade was a 2.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Vera Therapeutics Stock Performance

Shares of VERA stock opened at $40.79 on Friday. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19. Vera Therapeutics, Inc. has a 12-month low of $18.53 and a 12-month high of $56.05. The business’s 50 day moving average is $46.32 and its two-hundred day moving average is $35.49. The company has a market capitalization of $2.86 billion, a P/E ratio of -8.75 and a beta of 1.16.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Wednesday, February 25th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same period last year, the business earned ($0.72) earnings per share. Analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Hedge Funds Weigh In On Vera Therapeutics

Institutional investors have recently bought and sold shares of the company. Capricorn Fund Managers Ltd purchased a new stake in shares of Vera Therapeutics during the 3rd quarter valued at approximately $13,097,000. Swedbank AB purchased a new stake in Vera Therapeutics in the 3rd quarter valued at about $1,453,000. Squarepoint Ops LLC lifted its position in Vera Therapeutics by 232.0% in the second quarter. Squarepoint Ops LLC now owns 57,519 shares of the company’s stock valued at $1,355,000 after buying an additional 40,196 shares during the last quarter. Bollard Group LLC acquired a new position in Vera Therapeutics in the second quarter valued at about $1,509,000. Finally, SG Americas Securities LLC purchased a new position in Vera Therapeutics during the third quarter worth about $911,000. 99.21% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on VERA. Bank of America lifted their target price on shares of Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, December 19th. JPMorgan Chase & Co. lowered their price objective on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating on the stock in a report on Friday, December 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a research note on Friday, December 5th. Finally, Pivotal Research set a $73.00 price target on Vera Therapeutics in a research report on Friday, December 5th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Vera Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $78.80.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.